Can Ethics Review Catch Up to the CBD Craze?
CBD, a non-psychoactive cannabinoid, is experiencing a massive surge in popularity, but clinical research lags behind in verifying effective uses.
Quorum/Kinetiq Acquisition & Integration:
What You Need to Know
On March 5, 2019, Advarra announced its acquisition of Quorum Review IRB and Kinetiq, the research and technology consulting division of Quorum. We’ve assembled this FAQ to address some of…
After the Compliance Date: Revised Common Rule FAQs (Or: Why We Cancelled Our February Webinar)
The bad news is we cancelled our webinar on the revised Common Rule. The good news? We cancelled it because it seems the revised Common Rule implementation and transition have…
Informed Consent Changes in the Revised Common Rule
Many of the revised Common Rule’s changes aim to make informed consent more meaningful, so that research subjects have the...
Do I Need to Comply With the Revised Common Rule?
Most requirements of the revised Common Rule go into effect January 21, 2019*. While many US researchers are aware of...
Reporting to the IRB: Serious Adverse Events (SAEs) in Drug Studies
At Advarra, we often get questions about exactly what events should be reported to the IRB. We understand that “reportable...
Infection Control and Biosafety in Gene Therapy Research
Gene therapy research has moved from the realm of science fiction to mainstream clinical research. The maturation of this field...
Integration Update: Leading Compliance Adherence
The Advarra team is proud to announce that all major integration activities are now complete. SOPs have been harmonized; staff...
ICH-GCP Guidelines and Research Conducted in the US
When research is being conducted in multiple countries, determining which regulations apply to which country’s sites can sometimes be complicated....
What’s the Difference Between Right to Try and Expanded Access?
The right to try movement and recent passage of the federal right to try law have renewed public interest in...
